Gout News and Research RSS Feed - Gout News and Research
The most common inflammatory arthritis in men over the age of 40, gout is characterized by sudden and severe episodes of pain, tenderness, redness, stiffness and swelling of joints. Gout is most often felt in the large joint of the big toe, but it can affect other joints such as the instep, ankle, heel, knee, wrist, finger and elbow. Today, more than two million Americans suffer the pain and inconvenience of gout, but the good news is that gout can be managed and controlled with medication and through adjustments to diet and lifestyle.
Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. [More]
Pfizer does not meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer does not meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib. [More]
BioCryst first quarter revenues increase to $12.2 million

BioCryst first quarter revenues increase to $12.2 million

BioCryst Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2012. [More]
High fructose intake may increase risk of NFALD in obese people

High fructose intake may increase risk of NFALD in obese people

Obese people who consume increased amounts of fructose, a type of sugar that is found in particular in soft drinks and fruit juices, are at risk for nonalcoholic fatty liver disease (NFALD) and more its more severe forms, fatty inflammation and scarring. [More]
Teens with high levels of uric acid at increased risk for high blood pressure

Teens with high levels of uric acid at increased risk for high blood pressure

Teens with high levels of uric acid appear to be at increased risk for high blood pressure, according to results of research from scientists at the Johns Hopkins Children's Center. [More]

AstraZeneca first quarter revenue down 11% to $7,349 million

First quarter results reflect challenging revenue picture. Pipeline strengthened by Amgen collaboration, the agreement to acquire Ardea Biosciences and positive CHMP opinion for FORXIGATM (dapagliflozin) in Europe. [More]

First study to examine soda's effect on stroke risk

Researchers from Cleveland Clinic's Wellness Institute and Harvard University have found that greater consumption of sugar-sweetened and low-calorie sodas is associated with a higher risk of stroke. Conversely, consumption of caffeinated or decaffeinated coffee was associated with a lower risk. [More]

Takeda enters definitive agreement to acquire URL Pharma

Takeda Pharmaceutical Company Limited and URL Pharma Inc. jointly announced today that Takeda's wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma – a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments. [More]

Biochemists determine atomic structure of new ABC transporter

Proteins belonging to the large and important family of ABC transporters have been associated with metabolic diseases and can cause resistance to antibiotics. Biochemists from the University of Zurich and the NCCR Structural Biology have succeeded in determining the atomic structure of a new ABC transporter. The insights gained could give rise to new therapies to treat multi-resistant bacteria, cystic fibrosis or gout, for instance. [More]
3SBio fourth quarter total net revenues increase 38.2% to RMB139.9M

3SBio fourth quarter total net revenues increase 38.2% to RMB139.9M

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2011. [More]